" class="no-js "lang="en-US"> Bio-Thera Announces First Patient Dosed in Solid Tumors Study
Saturday, April 01, 2023

Bio-Thera Solutions Announces First Patient Dosed in Study for the Treatment of Advanced Solid Tumors

Bio-Thera Solutions, a commercial-stage pharmaceutical company, has announced that dosing has begun in a Phase 1 clinical study evaluating BAT8007, an antibody-drug conjugate (ADC) that targets Nectin-4. The multicenter, open-label Phase 1 clinical study in patients with advanced solid tumors aims to evaluate the safety and tolerability of BAT8007. Key objectives of the Bio-Thera study are to determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and to evaluate the pharmacokinetics and preliminary efficacy in patients with advanced solid tumors.

BAT8007 is an antibody-drug conjugate (ADC) targeting Nectin-4 designed for the treatment of solid tumors. Nectin-4 (Nectin cell adhesion molecule 4) belongs to the nectin subfamily of immunoglobulin-like adhesion molecules that participate in Ca(2+)-independent cell-cell adhesion. Nectin-4 has high expression levels in a normal embryo and fetal tissues, while those expression levels decline in adulthood and has limited distribution in healthy tissues.

Nectin-4 is overexpressed in a variety of solid tumors, such as urothelial carcinoma, breast cancer, non-small cell lung cancer, pancreatic cancer, esophageal cancer and head and neck cancer, etc. High expression levels of Nectin-4 in tumors is associated with poor prognosis for patients. Nectin-4 is a validated drug target with one approved drug for the treatment of solid tumors and is a target of high interest for new drug discovery.

BAT8007 was developed by using Bio-Thera’s proprietary ADC linker-payload that includes a cleavable but systemically stable linker, a small molecule topoisomerase I inhibitor and high DAR. The small molecule topoisomerase I inhibitor payload carried by BAT8007 has a strong cell membrane penetration ability. Consequently, when targeted cancer cells are killed, the payload has shown to be released and kill nearby cancer cells, producing a bystander effect, which has the potential to overcome the heterogeneity of the tumor. BAT8007 has demonstrated high anti-tumor activity, good stability, and safety in both in vitro and in vivo pharmacological studies.

Companies In This Post

  1. Insmed Completes Enrollment of Adult Patients in Phase 3 ASPEN Study of Brensocatib in Bronchiectasis Read more
  2. NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business Read more
  3. Flare Therapeutics Further Strengthens Leadership Team with Key Executive Appointments and Promotions Read more
  4. Sensorion Appoints Khalil Barrage as Interim Chairman of the Board Read more
  5. Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China Read more